3-methanesulfonylquinolines as GABA B enhancers

Details 3-methanesulfonylquinolines as GABA B enhancers 3-methanesulfonylquinolines as GABA B enhancers

2006-06-01

2010-06-01

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S155000, C546S156000

Reexamination Certificate

active

07728142

ABSTRACT:
The present invention relates to compounds of formula Iwherein R1, R2and R3are as defined in the specification, which are active at the GABABreceptor and which can be used for the treatment of CNS disorders.

REFERENCES:
patent: 4952573 (1990-08-01), LeClerc et al.
patent: 6313146 (2001-11-01), Van Wagenen et al.
patent: 6649626 (2003-11-01), Dodd et al.
patent: 7250515 (2007-07-01), Chen et al.
patent: 0 334 491 (1989-09-01), None
patent: 0 345 068 (1989-12-01), None
patent: 0 419 247 (1991-03-01), None
patent: WO 96/14319 (1996-05-01), None
patent: WO 01/29030 (2001-04-01), None
patent: WO 01/56990 (2001-08-01), None
patent: WO 03/080580 (2003-10-01), None
patent: WO 03/090731 (2003-11-01), None
patent: WO 2004/043930 (2004-05-01), None
patent: WO 2005/026125 (2005-03-01), None
patent: WO 2005/040124 (2005-05-01), None
Hill et al., Nature, 290, pp. 149-152, (1981).
Billinton et al. Trends in Neurosci., 24, 277-282, (2001).
Bowery et al., Pharmacol. Rev.. 54, pp. 247-264, (2002).
Vacher et al., Curr. Drug Targets, CNS Neurol. Disord. 2, pp. 248-259, (2003).
Bettler et al., Physiol Rev. 84, pp. 835-867, (2004).
Kaupmann et al., Nature, 386, pp. 239-246, (1997).
Kaupmann et al., Nature, 396, pp. 683-687, (1998).
Pin et al., Pharmaco.. Ther. 98, pp. 325-354, (2003).
Galvez et al., J. Biol. Chem., 275, pp. 41166-41174, (2000).
Havlickova et al., Mol. Pharmacol. 62, pp. 343-350, (2002).
Kniazeff et al.,J. Neurosci., 22, pp. 7352-7361, (2002).
Schuler et al., Neuron, 31, pp. 47-58, (2001).
Peters et al., Neurogenetics, 2, pp. 47-54, (1998).
Mondabon et al., Am. J. Med. Genet 122B/1, p. 134, (2003).
Gassmann et al., J Neurosci. 24, pp. 6086-6097, (2004).
Misgeld et al., Prog. Neurobiol. 46, pp. 423-462, (1995).
Enna et al., Life Sci, 62, pp. 1525-1530, (1998).
McCarson et al., Neuropharmacology, 38, pp. 1767-1773, (1999).
Brebner et al., Neuropharmacology, 38, pp. 1797-1804, (1999).
Paterson et al., Psychopharmacology, 172, pp. 179-186, (2004).
Breslow et al., Am. J. Psychiatry, 146, pp. 353-356, (1989).
Drake et al., Ann. Pharmacother. 37., pp. 1177-1181, (2003).
Bortolato et al., Psychopharmacology, 171, pp. 322-330, (2004).
Urwyler et al., Mol. Pharmacol., 60, pp. 963-971, (2001).
Pin et al., Mol. Pharmaco1.,60, pp. 881-884, (2001).
Binet et al., J Biol Chem., 279, pp. 29085-29091, (2004).
Wigger et al., Neuropsychopharmacology, pp. 1-14, (2004).
Urwyler et al., J. Pharmacol. Exp. Ther., 307, pp. 322-330, (2003).
Cryan et al., J Pharmacol Exp Ther., 310, pp. 952-963, (2004).
Smith et al., Psychopharmacology, 173, pp. 105-111, (2004).
Knoflach et al., Proc. Natl. Acad. Sci., USA, 98, pp. 13402-13407, (2001).
Wichmann et al., Il Farmaco, 57, pp. 989-992, (2002).
Hammerland et al., Mol. Pharmacol., 53, pp. 1083-1088, (1998).
O'Brien et al., J. Pharmaco. Exp. Ther., 309, pp. 568-577 (2004).
Schaffhauser et al., Mol. Pharmacol., 64, pp. 798-810, (2003).
Mombereau et al., Neuropsychopharmacology, 29, pp. 1050-1062, 2004.
Fuson, R.C., et al., J. Am. Chem. Soc., vol. 79, pp. 3477-3480 (1957).
Walser, A., et al., J. Heterocycl. Chem., vol. 13, pp. 131-133 (1976).
Sinsky, M.D., et al., J. Heterocycl. Chem., vol. 21, pp. 759-768 (1984).
Arcadi, A., et al., Synlett., pp. 203-206 (2003).
Sato, Susumu, et al., Chemical Abstract of JP 2002 371078 A2 XP002367441.
Chemical Abstracts, XP002367442, Publ. Date Apr. 25, 2003.
Chemical Abstracts, XP002367443, Publ. Date Sep. 27, 2004.
Urwyler, S., et al., Molecular Pharmacology, vol. 60, No. 5, Nov. 2001, pp. 963-971.
Urwyler, S., et al., American Chemical Society, Abstracts of Paper at the National Meeting of the ACS, Washington, D.C., vol. 225, No. 1/2, Mar. 23, 2003, p. MEDI 317.
Mohamed, et al.,Synthesis and antimicrobial activity of some newer 6-iodo-2-methyl-3-substituted 4(3H)-quinazolinones, J. Serb. Chem. vol. 57(10) pp. 629-633 (1992) XP002397916.

Affiliated with

Also associated with

Rating

3-methanesulfonylquinolines as GABA B enhancers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3-methanesulfonylquinolines as GABA B enhancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-methanesulfonylquinolines as GABA B enhancers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4208865